GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Sloan Ratio %

Albany Molecular Research (Albany Molecular Research) Sloan Ratio % : 7.94% (As of Jun. 2017)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Albany Molecular Research's Sloan Ratio for the quarter that ended in Jun. 2017 was 7.94%.

As of Jun. 2017, Albany Molecular Research has a Sloan Ratio of 7.94%, indicating the company is in the safe zone and there is no funny business with accruals.


Albany Molecular Research Sloan Ratio % Historical Data

The historical data trend for Albany Molecular Research's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Sloan Ratio % Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.73 -1.16 30.64 20.77 7.97

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.82 14.69 7.97 9.13 7.94

Competitive Comparison of Albany Molecular Research's Sloan Ratio %

For the Biotechnology subindustry, Albany Molecular Research's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albany Molecular Research's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albany Molecular Research's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Albany Molecular Research's Sloan Ratio % falls into.



Albany Molecular Research Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Albany Molecular Research's Sloan Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2016 )-Cash Flow from Operations (A: Dec. 2016 )
-Cash Flow from Investing (A: Dec. 2016 ))/Total Assets (A: Dec. 2016 )
=(-70.171-26.635
--193.197)/1209.648
=7.97%

Albany Molecular Research's Sloan Ratio for the quarter that ended in Jun. 2017 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2017 )
=(-59.775-19.914
--178.329)/1242.374
=7.94%

Albany Molecular Research's Net Income for the trailing twelve months (TTM) ended in Jun. 2017 was -23.425 (Sep. 2016 ) + -15.411 (Dec. 2016 ) + -10.692 (Mar. 2017 ) + -10.247 (Jun. 2017 ) = $-59.8 Mil.
Albany Molecular Research's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2017 was -10.013 (Sep. 2016 ) + 21.407 (Dec. 2016 ) + -6.41 (Mar. 2017 ) + 14.93 (Jun. 2017 ) = $19.9 Mil.
Albany Molecular Research's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2017 was -156.272 (Sep. 2016 ) + -11.42 (Dec. 2016 ) + -4.062 (Mar. 2017 ) + -6.575 (Jun. 2017 ) = $-178.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albany Molecular Research  (NAS:AMRI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2017, Albany Molecular Research has a Sloan Ratio of 7.94%, indicating the company is in the safe zone and there is no funny business with accruals.


Albany Molecular Research Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines